BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Li J, He T, Ouyang Y, Huang Y, Liu Q, Wang P, Ding J. Two predictive precision medicine tools for hepatocellular carcinoma. Cancer Cell Int 2019;19:290. [PMID: 31754347 DOI: 10.1186/s12935-019-1002-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li B, Min J, Liang WR, Zhang GQ, Wu JJ, Jin K, Huang W, Ying CY, Chao M. Use of magnetic resonance elastography for assessing liver functional reserve: A clinical study. World J Gastroenterol 2015; 21(24): 7522-7528 [PMID: 26139999 DOI: 10.3748/wjg.v21.i24.7522] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
3 Duke E, Deng J, Ibrahim SM, Lewandowski RJ, Ryu RK, Sato KT, Miller FH, Kulik L, Mulcahy MF, Larson AC. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol. 2010;21:515-521. [PMID: 20172741 DOI: 10.1016/j.jvir.2009.11.020] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
4 Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15(20): 2506-2511 [PMID: 19469001 DOI: 10.3748/wjg.15.2506] [Cited by in CrossRef: 108] [Cited by in F6Publishing: 101] [Article Influence: 8.3] [Reference Citation Analysis]
5 Noda I, Kitamoto M, Nakahara H, Hayashi R, Okimoto T, Monzen Y, Yamada H, Imagawa M, Hiraga N, Tanaka J, Chayama K. Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2010;45:105-12. [PMID: 19866332 DOI: 10.1007/s00535-009-0131-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
6 Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, Cappelli A, Antonino M, Modestino F, Brandi N, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med 2021;11:1041. [PMID: 34683182 DOI: 10.3390/jpm11101041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Cortes-Mancera F, Loureiro CL, Hoyos S, Restrepo JC, Correa G, Jaramillo S, Norder H, Pujol FH, Navas MC. Etiology and Viral Genotype in Patients with End-Stage Liver Diseases admitted to a Hepatology Unit in Colombia. Hepat Res Treat. 2011;2011:363205. [PMID: 21941645 DOI: 10.1155/2011/363205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
8 Marinho RT, Giria J, Moura MC. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993-2005). World J Gastroenterol 2007; 13(10): 1522-1527 [PMID: 17461443 DOI: 10.3748/wjg.v13.i10.1522] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lungren MP, Towbin AJ, Roebuck DJ, Monroe EJ, Gill AE, Thakor A, Towbin RB, Cahill AM, Matthew Hawkins C. Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions. Pediatr Radiol. 2018;48:555-564. [PMID: 29362840 DOI: 10.1007/s00247-018-4068-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
10 Eichler K, Zangos S, Mack MG, Hammerstingl R, Gruber-Rouh T, Gallus C, Vogl TJ. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol. 2012;41:1213-1220. [PMID: 22842404 DOI: 10.3892/ijo.2012.1572] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
11 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
12 Balbi M, Donadon V, Ghersetti M, Grazioli S, Valentina GD, Gardenal R, Mas MD, Casarin P, Zanette G, Miranda C. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy. Int J Environ Res Public Health. 2010;7:1366-1378. [PMID: 20617035 DOI: 10.3390/ijerph7041366] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
13 Yu X, Xia W, Zhang T, Wang H, Xie Y, Yang J, Miao J. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol 2010;92:276-82. [PMID: 20697855 DOI: 10.1007/s12185-010-0654-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
14 Modica TME, Dituri F, Mancarella S, Pisano C, Fabregat I, Giannelli G. Calcium Regulates HCC Proliferation as well as EGFR Recycling/Degradation and Could Be a New Therapeutic Target in HCC. Cancers (Basel) 2019;11:E1588. [PMID: 31635301 DOI: 10.3390/cancers11101588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Man XB, Tang L, Qiu XH, Yang LQ, Cao HF, Wu MC, Wang HY. Expression of cytochrome P4502E1 gene in hepatocellular carcinoma. World J Gastroenterol 2004; 10(11): 1565-1568 [PMID: 15162526 DOI: 10.3748/wjg.v10.i11.1565] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
16 Amaya MJ, Nathanson MH. Calcium signaling in the liver. Compr Physiol 2013;3:515-39. [PMID: 23720295 DOI: 10.1002/cphy.c120013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 1.2] [Reference Citation Analysis]
17 Masuzaki R, Tateishi R, Yoshida H, Sato T, Ohki T, Goto T, Yoshida H, Sato S, Sugioka Y, Ikeda H. Assessing liver tumor stiffness by transient elastography. Hepatol Int. 2007;1:394-397. [PMID: 19669335 DOI: 10.1007/s12072-007-9012-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
18 Neuberger J. Developments in liver transplantation. Gut 2004;53:759-68. [PMID: 15082598 DOI: 10.1136/gut.2003.024927] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
19 Cho Y, Kim JW, Kim JK, Lee KS, Lee JI, Lee HW, Lee KH, Joo SM, Lim JH, Lee IJ. Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1612. [PMID: 32570869 DOI: 10.3390/cancers12061612] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Lee YH, Lee JI. Metastatic carcinoma of the oral region: An analysis of 21 cases. Med Oral Patol Oral Cir Bucal 2017;22:e359-65. [PMID: 28390123 DOI: 10.4317/medoral.21566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
21 Da Fonseca LG, Leonardi PC, Hashizume PH, Sansone F, Saud LR, Carrilho FJ, Herman P. A multidisciplinary approach to peritoneal metastasis from hepatocellular carcinoma: clinical features, management and outcomes. Clin Exp Hepatol 2022;8:42-8. [PMID: 35415264 DOI: 10.5114/ceh.2022.114297] [Reference Citation Analysis]
22 Banerjee S, Saluja A. Minnelide, a novel drug for pancreatic and liver cancer. Pancreatology 2015;15:S39-43. [PMID: 26122306 DOI: 10.1016/j.pan.2015.05.472] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
23 Liu J, Wang K, Yan Z, Xia Y, Li J, Shi L, Zou Q, Wan X, Jiao B, Wang H, Wu M, Zhang Y, Shen F. Axl Expression Stratifies Patients with Poor Prognosis after Hepatectomy for Hepatocellular Carcinoma. PLoS One 2016;11:e0154767. [PMID: 27182739 DOI: 10.1371/journal.pone.0154767] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
24 Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Li HX, Qian BY, Hao XS. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis--a randomized study. World J Surg. 2006;30:2004-2011; discussion 2012-2013. [PMID: 17058027 DOI: 10.1007/s00268-006-0271-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
25 Granito A, Bolondi L. Medical treatment of hepatocellular carcinoma. Mediterr J Hematol Infect Dis 2009;1:e2009021. [PMID: 21415957 DOI: 10.4084/MJHID.2009.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
27 Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, Nishikaku F. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-483. [PMID: 19104812 DOI: 10.1007/s00280-008-0895-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
28 Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 2020;7:117-31. [PMID: 32984089 DOI: 10.2147/JHC.S248314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Xu W, Huang JJ, Cheung PC. Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One 2012;7:e34406. [PMID: 22470568 DOI: 10.1371/journal.pone.0034406] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
30 Pazienza V, Panebianco C, Andriulli A. Hepatitis viruses exploitation of host DNA methyltransferases functions. Clin Exp Med 2016;16:265-72. [PMID: 26148656 DOI: 10.1007/s10238-015-0372-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
31 Liu SY, Zhang RL, Kang H, Fan ZJ, Du Z. Human liver tissue metabolic profiling research on hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(22): 3423-3432 [PMID: 23801834 DOI: 10.3748/wjg.v19.i22.3423] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
32 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Reference Citation Analysis]
33 Salama HM, Abdel-Haleem H, Taha FM, Abdel-Azeez RA, Marzaban RN, El-Nahaas SM, Darwish T. Plasma proteosome level as a potential marker for hepatocellular carcinoma. Arab J Gastroenterol 2013;14:87-93. [PMID: 24206735 DOI: 10.1016/j.ajg.2013.09.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
34 Wang Z, Tan J, McConville C, Kannappan V, Tawari PE, Brown J, Ding J, Armesilla AL, Irache JM, Mei QB, Tan Y, Liu Y, Jiang W, Bian XW, Wang W. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine 2017;13:641-57. [PMID: 27521693 DOI: 10.1016/j.nano.2016.08.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 6.2] [Reference Citation Analysis]
35 Takizawa D, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Katakai K, Kojima A, Matsuzaki Y, Mori M. Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Clinical Characteristics, Prognosis, and Patient Survival Analysis. Dig Dis Sci 2007;52:3290-5. [DOI: 10.1007/s10620-007-9808-2] [Cited by in Crossref: 94] [Cited by in F6Publishing: 85] [Article Influence: 6.3] [Reference Citation Analysis]
36 Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:475. [PMID: 20813065 DOI: 10.1186/1471-2407-10-475] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 13.7] [Reference Citation Analysis]
37 Kiriyama S, Yokoyama S, Ueno M, Hayami S, Ieda J, Yamamoto N, Yamaguchi S, Mitani Y, Nakamura Y, Tani M, Mishra L, Shively JE, Yamaue H. CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma. Ann Surg Oncol 2014;21 Suppl 4:S505-14. [PMID: 24390710 DOI: 10.1245/s10434-013-3460-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
38 Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007;97:582-588. [PMID: 17687341 DOI: 10.1038/sj.bjc.6603901] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
39 Yu X, Xia W, Zhang T, Wang H, Xie Y, Yang J, Miao J. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol. 2010;92:276-282. [PMID: 20697855 DOI: 10.1007/s12185-010-0654-1.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Sugumar K, Markt SC, Hue JJ, Hoehn RS, Lee RT, Chavin KD, Rothermel LD, Winter JM, Hardacre JM, Ammori JB, Ocuin LM. Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. HPB (Oxford) 2021:S1365-182X(21)01690-7. [PMID: 34872866 DOI: 10.1016/j.hpb.2021.10.023] [Reference Citation Analysis]
41 Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci 2019;24:86. [PMID: 31741658 DOI: 10.4103/jrms.JRMS_1017_18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
42 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(16): 2021-2025 [DOI: 10.11569/wcjd.v13.i16.2021] [Reference Citation Analysis]
43 Jingting J, Changping W, Ning X, yibei Z, Jun W, Mei J, Bin X, Peter NE, Xueguan Z. Clinical evaluation of serum alpha-fetoprotein-IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. J Clin Lab Anal 2009;23:213-8. [PMID: 19623644 DOI: 10.1002/jcla.20321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
44 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
45 Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010; 16(24): 3025-3032 [PMID: 20572306 DOI: 10.3748/wjg.v16.i24.3025] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
46 Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009;9:31. [PMID: 19432967 DOI: 10.1186/1471-230x-9-31] [Cited by in Crossref: 101] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
47 Guo Z, Zhang J, Jiang JH, Li LQ, Xiang BD. Obesity Does Not Influence Outcomes in Hepatocellular Carcinoma Patients following Curative Hepatectomy. PLoS One 2015;10:e0125649. [PMID: 25965529 DOI: 10.1371/journal.pone.0125649] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
48 Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(11): 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
49 Tovuu LO, Imura S, Utsunomiya T, Morine Y, Ikemoto T, Arakawa Y, Mori H, Hanaoka J, Kanamoto M, Sugimoto K, Iwahashi S, Saito Y, Yamada S, Asanoma M, Miyake H, Shimada M. Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma. Int J Clin Oncol 2013;18:651-6. [PMID: 22706704 DOI: 10.1007/s10147-012-0432-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
50 Naumann M, Bonsall R, Gupta R. Chemoembolization with drug-eluting beads complicated by intrahepatic biloma. Semin Intervent Radiol 2011;28:212-7. [PMID: 22654265 DOI: 10.1055/s-0031-1280667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
51 Núñez O, Fernández-Martínez A, Majano PL, Apolinario A, Gómez-Gonzalo M, Benedicto I, López-Cabrera M, Boscá L, Clemente G, García-Monzón C, Martín-Sanz P. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004;53:1665-72. [PMID: 15479690 DOI: 10.1136/gut.2003.038364] [Cited by in Crossref: 113] [Cited by in F6Publishing: 112] [Article Influence: 6.3] [Reference Citation Analysis]
52 Qiao Z, Zhang Y, Ge M, Liu S, Jiang X, Shang Z, Liu H, Cao C, Xiao H. Cancer Cell Derived Small Extracellular Vesicles Contribute to Recipient Cell Metastasis Through Promoting HGF/c-Met Pathway. Mol Cell Proteomics 2019;18:1619-29. [PMID: 31196968 DOI: 10.1074/mcp.RA119.001502] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
53 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.0] [Reference Citation Analysis]
54 Zhang J, Jiang TY, Jiang BG, Yang C, Tan YX, Yang N, Pan YF, Ding ZW, Yang GZ, Wu MC, Dong LW, Wang HY. RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma. Oncotarget 2015;6:3432-42. [PMID: 25605019 DOI: 10.18632/oncotarget.3092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
55 Deng J, Virmani S, Young J, Harris K, Yang GY, Rademaker A, Woloschak G, Omary RA, Larson AC. Diffusion-weighted PROPELLER MRI for quantitative assessment of liver tumor necrotic fraction and viable tumor volume in VX2 rabbits. J Magn Reson Imaging 2008;27:1069-76. [PMID: 18407540 DOI: 10.1002/jmri.21327] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
56 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
57 Lim SC, Choi JE, Kang HS, Han SI. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer 2010;126:1582-95. [PMID: 19728331 DOI: 10.1002/ijc.24853] [Cited by in Crossref: 11] [Cited by in F6Publishing: 26] [Article Influence: 0.9] [Reference Citation Analysis]
58 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
59 Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, Hou SM, Wu CH, Chen TK. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein tumor thrombosis. World J Gastroenterol 2003; 9(12): 2666-2670 [PMID: 14669309 DOI: 10.3748/wjg.v9.i12.2666] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
60 Wang Z, Wu N, Tesfaye A, Feinstone S, Kumar A. HCV infection-associated hepatocellular carcinoma in humanized mice. Infect Agent Cancer 2015;10:24. [PMID: 26217396 DOI: 10.1186/s13027-015-0018-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
61 Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-1868. [PMID: 15870713 DOI: 10.1038/sj.bjc.6602590] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 6.8] [Reference Citation Analysis]
62 Cao T, Yi SJ, Wang LX, Zhao JX, Xiao J, Xie N, Zeng Z, Han Q, Tang HO, Li YK, Zou J, Wu Q. Identification of the DNA Replication Regulator MCM Complex Expression and Prognostic Significance in Hepatic Carcinoma. Biomed Res Int 2020;2020:3574261. [PMID: 32964028 DOI: 10.1155/2020/3574261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
63 Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res 2009;28:20. [PMID: 19216803 DOI: 10.1186/1756-9966-28-20] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.0] [Reference Citation Analysis]
64 Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin. 2010;31:1165-1171. [PMID: 20676120 DOI: 10.1038/aps.2010.94] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]